These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

602 related articles for article (PubMed ID: 23001349)

  • 1. Controlling escape from angiogenesis inhibitors.
    Sennino B; McDonald DM
    Nat Rev Cancer; 2012 Oct; 12(10):699-709. PubMed ID: 23001349
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Sabotaging Role of Myeloid Cells in Anti-Angiogenic Therapy: Coordination of Angiogenesis and Immune Suppression by Hypoxia.
    Li C; Liu T; Bazhin AV; Yang Y
    J Cell Physiol; 2017 Sep; 232(9):2312-2322. PubMed ID: 27935039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vascular endothelial growth factor as a therapeutic target in cancer.
    Bergsland EK
    Am J Health Syst Pharm; 2004 Nov; 61(21 Suppl 5):S4-11. PubMed ID: 15552621
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanisms of drug resistance to vascular endothelial growth factor (VEGF) inhibitors.
    Tavakoli J; Aragon-Ching JB
    Anticancer Agents Med Chem; 2010 Oct; 10(8):593-600. PubMed ID: 21182470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent advances in angiogenesis, anti-angiogenesis and vascular targeting.
    Bikfalvi A; Bicknell R
    Trends Pharmacol Sci; 2002 Dec; 23(12):576-82. PubMed ID: 12457776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.
    Zhao Y; Adjei AA
    Oncologist; 2015 Jun; 20(6):660-73. PubMed ID: 26001391
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The VEGF pathway in cancer and disease: responses, resistance, and the path forward.
    Kieran MW; Kalluri R; Cho YJ
    Cold Spring Harb Perspect Med; 2012 Dec; 2(12):a006593. PubMed ID: 23209176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapies.
    Shojaei F; Ferrara N
    Drug Resist Updat; 2008 Dec; 11(6):219-30. PubMed ID: 18948057
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [VEGF, anti-vEGF and diseases].
    Corvol P
    Bull Acad Natl Med; 2008 Feb; 192(2):289-300; discussion 300-2. PubMed ID: 18819684
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vascular endothelial growth factor as a target for anticancer therapy.
    Ferrara N
    Oncologist; 2004; 9 Suppl 1():2-10. PubMed ID: 15178810
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blocking angiogenesis and tumorigenesis with GFA-116, a synthetic molecule that inhibits binding of vascular endothelial growth factor to its receptor.
    Sun J; Blaskovich MA; Jain RK; Delarue F; Paris D; Brem S; Wotoczek-Obadia M; Lin Q; Coppola D; Choi K; Mullan M; Hamilton AD; Sebti SM
    Cancer Res; 2004 May; 64(10):3586-92. PubMed ID: 15150116
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beyond Angiogenesis: Exploiting Angiocrine Factors to Restrict Tumor Progression and Metastasis.
    Singhal M; Augustin HG
    Cancer Res; 2020 Feb; 80(4):659-662. PubMed ID: 31831463
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biomarkers: New VEGF model-based biomarker.
    Hutchinson L
    Nat Rev Clin Oncol; 2013 Jul; 10(7):366. PubMed ID: 23736646
    [No Abstract]   [Full Text] [Related]  

  • 14. LHT7, a chemically modified heparin, inhibits multiple stages of angiogenesis by blocking VEGF, FGF2 and PDGF-B signaling pathways.
    Chung SW; Bae SM; Lee M; Al-Hilal TA; Lee CK; Kim JK; Kim IS; Kim SY; Byun Y
    Biomaterials; 2015 Jan; 37():271-8. PubMed ID: 25453957
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vessel abnormalization: another hallmark of cancer? Molecular mechanisms and therapeutic implications.
    De Bock K; Cauwenberghs S; Carmeliet P
    Curr Opin Genet Dev; 2011 Feb; 21(1):73-9. PubMed ID: 21106363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-VEGF and beyond: shaping a new generation of anti-angiogenic therapies for cancer.
    Bertolini F; Marighetti P; Martin-Padura I; Mancuso P; Hu-Lowe DD; Shaked Y; D'Onofrio A
    Drug Discov Today; 2011 Dec; 16(23-24):1052-60. PubMed ID: 21875682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of novel antiangiogenic anticancer activities of deguelin targeting hypoxia-inducible factor-1 alpha.
    Oh SH; Woo JK; Jin Q; Kang HJ; Jeong JW; Kim KW; Hong WK; Lee HY
    Int J Cancer; 2008 Jan; 122(1):5-14. PubMed ID: 17764071
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vascular endothelial cell growth factor (VEGF), an emerging target for cancer chemotherapy.
    Shinkaruk S; Bayle M; Laïn G; Déléris G
    Curr Med Chem Anticancer Agents; 2003 Mar; 3(2):95-117. PubMed ID: 12678905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms of resistance to antiangiogenesis therapy.
    Azam F; Mehta S; Harris AL
    Eur J Cancer; 2010 May; 46(8):1323-32. PubMed ID: 20236818
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The multifaceted activity of VEGF in angiogenesis - Implications for therapy responses.
    Moens S; Goveia J; Stapor PC; Cantelmo AR; Carmeliet P
    Cytokine Growth Factor Rev; 2014 Aug; 25(4):473-82. PubMed ID: 25169850
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.